Vividion Therapeutics has dosed the first subject in a Phase I trial of an oral inhibitor, VVD-159642, aimed at treating ...

Revolution Medicines is a clinical-stage pharma company with a market cap of ~6 billion. Click here to find out why RVMD ...

Vividion Therapeutics, Inc. (Vividion) today announced that the first patient has been dosed in a Phase I clinical trial ...

Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept ... In this study, the researchers used RAS(ON) multi-selective inhibitors ...

"K-RAS is a gene that is an on-switch in many of these cancers," said Sohal. "Basically, it turns the cancer cells on, and these drugs try to turn that switch off, so the cancer cells stop growing.

Western-blot analysis of astrocytes infected with these vectors showed expression of activated Akt and Ras, verifying that these vectors indeed transfer expression of the appropriate gene products ...

it has become clear that KRAS-mutant cancers can quickly evolve to resist therapies targeted at one specific form of the gene mutation. "We've been excited by the prospect of RAS inhibition for ...

“Despite being a major driver in approximately 20% of cancers, the RAS gene has proven exceptionally difficult to target with drugs, largely due to its essential role in the RAS-PI3Kα signaling ...

Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept ... A new type of RAS inhibitor In this study, the researchers used ...